Evidence map›Paper›PMID 27717322›Full record

ArticleBMC nephrology2016

Ergocalciferol treatment does Not improve erythropoietin utilization and hospitalization rate in hemodialysis patients.

Gaurav Agarwal, Padam Hirachan, Jonathan Gelfond, Paolo Fanti, Claudia Hura, Shweta Bansal

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC nephrology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Gaurav AgarwalDepartment of Medicine, Division of Nephrology, University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA.
Padam HirachanDepartment of Medicine, Division of Nephrology, University of Texas Health Sciences Center at San Antonio, 7703 Floyd Curl Drive, MSC 7882, San Antonio, TX, 78229, USA.
Jonathan GelfondDepartment of Epidemiology and Biostatistics, University of Texas Health Sciences Center at San Antonio, San Antonio, TX, USA.
Paolo FantiDepartment of Medicine, Division of Nephrology, University of Texas Health Sciences Center at San Antonio, 7703 Floyd Curl Drive, MSC 7882, San Antonio, TX, 78229, USA.
Claudia HuraDepartment of Medicine, Division of Nephrology, University of Texas Health Sciences Center at San Antonio, 7703 Floyd Curl Drive, MSC 7882, San Antonio, TX, 78229, USA.
Shweta BansalDepartment of Medicine, Division of Nephrology, University of Texas Health Sciences Center at San Antonio, 7703 Floyd Curl Drive, MSC 7882, San Antonio, TX, 78229, USA. bansals3@uthscsa.edu.
The University of Texas Health Science Center at San Antonio · USSouth Texas Veterans Health Care System · USUniversity of Alabama at Birmingham · US

Funding

San Antonio OAIC - Research Education Component (REC)P30AG044271 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Adam Salmon, Elena Volpi · 2015 to 2026
$14.1M
NIA NIH HHS P30 AG044271
6 · The paper itself

Abstract

backgroundVitamin D (25-hydroxyvitamin D; 25[OH]D) deficiency (VDD) is highly prevalent in chronic kidney disease. The aim of this study was to evaluate the effect of oral ergocalciferol supplementation on requirement of erythropoietin (EPO) and active vitamin D analogues, and hospitalization rate in maintenance hemodialysis (HD) patients.

methodsThis retrospective cohort study included 186 patients who were on HD for 3 months and had 25(OH)D levels < 30 ng/ml. Over 1-year period, 107 patients were supplemented with protocol-based ergocalciferol (D

resultsBaseline characteristics were similar across two arms except higher serum ferritin, transferrin saturation and prevalence of stroke in D2 and higher coronary artery disease in control group with overall mean ± SD 25(OH)D level of 16.8 ± 7 ng/ml. At 12 months, 25(OH)D levels increased significantly in D

conclusionsOne-year of ergocalciferol supplementation was not associated with reduction in EPO requirement or hospitalization rate in HD patients with VDD. Further studies are warranted to determine definitive role of nutritional vitamin D in these patients.

Indexed as

Administration, OralAdultAgedCohort StudiesErgocalciferolsErythropoietinFemaleFollow-Up StudiesHospitalizationHumansMaleMiddle AgedRenal DialysisRenal Insufficiency, ChronicRetrospective StudiesTreatment OutcomeEPO protein, humanErgocalciferolsErythropoietinVitamin DVitaminsEPO requirementErgocalciferolHemodialysisHospitalizationVitamin D deficiency

Identifiers

PMID27717322
PMCPMC5055677
OpenAlexW2529692474

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.